STOCK TITAN

ImmunoPrecise Antibodies Ltd - IPA STOCK NEWS

Welcome to our dedicated news page for ImmunoPrecise Antibodies (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on ImmunoPrecise Antibodies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunoPrecise Antibodies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunoPrecise Antibodies's position in the market.

Rhea-AI Summary
IPA announces resignation of CFO Brad McConn, effective September 29, 2023. Kristin Taylor named interim CFO. Ms. Taylor brings extensive executive management and life sciences experience. Smooth transition expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.7%
Tags
none
-
Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) reports record quarterly revenue, up 21.3% YoY. Significant increase in net income before taxes, approximately $6 million difference from Q1 last year. Manufacturing facility revenue grows 44.0% YoY. Quarterly burn reduced to $1.6 million CAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
earnings
-
Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) to host earnings conference call on September 14, 2023, to discuss quarterly results and recent business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences earnings
News
Rhea-AI Summary
IPA appoints Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.78%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) reported a 6.7% increase in revenue for the fiscal year 2023, reaching $20.7 million. Adjusted for currency effects, the growth was 9.0%. The company also achieved its highest quarterly revenue total of $5.6 million. IPA's CEO, Dr. Jennifer Bath, expressed optimism for the future, highlighting the potential of their in silico suite of services and data management capabilities to drive growth in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
earnings
-
Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) reported a 6.7% increase in revenue for the fiscal year 2023, reaching $20.7 million. Adjusted for currency effects, the growth was 9.0%. The company also achieved its highest quarterly revenue total of $5.6 million. IPA's CEO, Dr. Jennifer Bath, expressed optimism for the future, highlighting the potential of their in silico suite of services and data management capabilities to drive growth in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
ImmunoPrecise Antibodies Ltd

Nasdaq:IPA

IPA Rankings

IPA Stock Data

40.00M
22.79M
13.56%
6.74%
1.67%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Victoria

About IPA

immunoprecise antibodies is a highly specialized customer focused life sciences company that provides custom antibody development and immunology services from its headquarters in beautiful victoria, bc, canada. our dedication to advancing antibody development has resulted in cutting-edge immunological innovations such as single-step cloning, rapid prime immunization strategies, and recombinant monoclonal technology. we pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving thorough and professional service. we customize your project to generate antibodies that meet your specific needs. over our 20+ year history, we have gained the trust of a diverse group of customers that include research agencies, universities, biotechnology and pharmaceutical companies of all sizes from around the globe. immunoprecise is pleased to announce its newest line of services, immunoprotect™. with immunoprotect™, the dna sequence of your mab is determined and ca